For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...
Total product sales -- $7.3 billion in fiscal Q3 2025, up 4% sequentially from Q2 2025, with growth driven by the HIV ...
Investor's Business Daily on MSN
Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations
Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention ...
People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...
Ten years ago, the Indiana community of Austin made headlines for its historic HIV outbreak brought on by intravenous drug ...
Dzidzai is one of 25 Community Adolescent Treatment Supporters (CATS) trained by the National Aids Council (NAC) and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback